Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination ...

Bio-Path Holdings (NASDAQ:BPTH) was planning to sell an additional 712,910 shares of BPTH stock to investors. It was pricing these shares at $25.95. However, the company’s stock has been trading below ...

A downtrend has been apparent in Bio-Path (BPTH) lately. While the stock has lost 8.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading ...

Bio-Path says the first patient treated with a higher dose in Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. Bio-Path reports its second-quarter financial results last ...

On Tuesday, Roth Capital revised its price target for Bio-Path Holdings Inc. (OTC:BPTH) to $2 from $9, while keeping a Buy rating on the shares. This adjustment came after the company provided an ...

Bio-Path Holdings Inc. Annual cash flow by MarketWatch. View BPTH net cash flow, operating cash flow, operating expenses and cash dividends.

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...